摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Boc-5-甲氧基吲哚-3-硼酸频那醇酯 | 1256359-99-5

中文名称
1-Boc-5-甲氧基吲哚-3-硼酸频那醇酯
中文别名
——
英文名称
tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-indole-1-carboxylate
英文别名
5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-1-Boc-indole;tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indol-1-carboxylate;tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate;tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1-carboxylate
1-Boc-5-甲氧基吲哚-3-硼酸频那醇酯化学式
CAS
1256359-99-5
化学式
C20H28BNO5
mdl
——
分子量
373.257
InChiKey
IRZPWZYCUJFBJB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    485.6±48.0 °C(Predicted)
  • 密度:
    1.10±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.73
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    58.9
  • 氢给体数:
    0
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:c881664280cfb67453f21d43aeef9250
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-Boc-5-Methoxyindole-3-boronic acid, pinacol ester
Synonyms: tert-Butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-5-Methoxyindole-3-boronic acid, pinacol ester
CAS number: 1256359-99-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C20H28BNO5
Molecular weight: 373.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-Boc-5-甲氧基吲哚-3-硼酸频那醇酯吡啶盐酸盐caesium carbonate 作用下, 以 1,4-二氧六环甲醇 为溶剂, 反应 24.5h, 生成 3-(2-aminopyrimidin-4-yl)-1H-indol-5-ol
    参考文献:
    名称:
    二嗪桥连双吲哚的一锅法合成及海洋生物碱海蒂那定 A 的简明合成
    摘要:
    二嗪桥连的双吲哚很容易从 N-Boc 保护的 3-碘代吲哚和 3-碘-7-氮杂吲哚在伪三组分反应中获得,该反应涉及一锅 Masuda 硼酸化 - Suzuki 芳基化序列。一些标题化合物显示出有希望的细胞毒性特性。海洋生物碱 hyrtinadine A 的非常简洁的全合成说明了这种方法的多功能性。
    DOI:
    10.1002/ejoc.201100680
  • 作为产物:
    参考文献:
    名称:
    二嗪桥连双吲哚的一锅法合成及海洋生物碱海蒂那定 A 的简明合成
    摘要:
    二嗪桥连的双吲哚很容易从 N-Boc 保护的 3-碘代吲哚和 3-碘-7-氮杂吲哚在伪三组分反应中获得,该反应涉及一锅 Masuda 硼酸化 - Suzuki 芳基化序列。一些标题化合物显示出有希望的细胞毒性特性。海洋生物碱 hyrtinadine A 的非常简洁的全合成说明了这种方法的多功能性。
    DOI:
    10.1002/ejoc.201100680
点击查看最新优质反应信息

文献信息

  • One-Pot Synthesis of Camalexins and 3,3′-Biindoles by the Masuda Borylation-Suzuki Arylation (MBSA) Sequence
    作者:Boris O. A. Tasch、Dragutin Antovic、Eugen Merkul、Thomas J. J. Müller
    DOI:10.1002/ejoc.201300133
    日期:2013.7
    The Masuda borylation/Suzuki arylation (MBSA) sequence starting from N-protected 3-iodoindoles has successfully been extended to the coupling of five-membered heterocycles and indoles in the arylation step, which could not be achieved with previously developed MBSA methods. By this approach the one-pot nature of the method as well as the use of a simple catalyst system has been retained. The applicability
    从 N 保护的 3-碘吲哚开始的 Masuda 硼酸化/铃木芳基化 (MBSA) 序列已成功扩展到芳基化步骤中五元杂环和吲哚的偶联,这是以前开发的 MBSA 方法无法实现的。通过这种方法,该方法的一锅法特性以及简单催化剂体系的使用得到了保留。该方法的适用性已通过 camalexins 和 3,3'-联吲哚的轻松合成得到证明,这些化合物由于其显着的抗真菌、抗菌和细胞毒性活性而受到特别关注。
  • [EN] NOVEL TRICYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES
    申请人:ABBOTT LAB
    公开号:WO2011068899A1
    公开(公告)日:2011-06-09
    The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    该发明提供了本公式(Ia)、(Ib)、(Ic)、(Id)、(Ie)、(If)、(Ig)、(Ih)、(Ii)、(Ij)、(Ik)或(Il)的化合物,以及在此定义的药学上可接受的盐、前药、生物活性代谢物、立体异构体和同分异构体,其中变量在此处定义。该发明的化合物对治疗免疫和肿瘤病症有用。
  • PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES
    申请人:Michaelides Michael R.
    公开号:US20110281842A1
    公开(公告)日:2011-11-17
    The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R 1 , R 2 , R 3 , R 4a , R 5 , and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.
    本发明涉及式(I)的化合物或药用可接受的盐,其中A、B、R1、R2、R3、R4a、R5和Z在描述中有定义。本发明还涉及制备所述化合物的方法,以及含有所述化合物的组合物,用于抑制aurora等激酶。
  • Hyrtinadine生物碱衍生物及其制备和在抗植物病毒和病菌中的应用
    申请人:南开大学
    公开号:CN110759893B
    公开(公告)日:2022-10-28
    本发明涉及hyrtinadine生物碱衍生物及其制备和在抗植物病毒和病菌中的应用。本发明的hyrtinadine生物碱衍生物显示出特别优异的抗植物病毒活性,能很好地抑制烟草花叶病毒(TMV),该类化合物同时表现出很好的抗植物病菌活性。
  • Novel Tricyclic Compounds
    申请人:Wishart Neil
    公开号:US20110190489A1
    公开(公告)日:2011-08-04
    The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
    本发明提供以下化合物的复合物(Ia),(Ib),(Ic),(Id),(Ie),(If),(Ig),(Ih),(Ii),(Ij),(Ik)或(Il),其中变量定义如下,其药学上可接受的盐,前药,生物活性代谢物,立体异构体和同分异构体。 本发明的化合物可用于治疗免疫和肿瘤疾病。
查看更多

同类化合物

(Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (R)-(+)-5'-苄氧基卡维地洛 (R)-卡洛芬 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (3Z)-3-(1H-咪唑-5-基亚甲基)-5-甲氧基-1H-吲哚-2-酮 (3Z)-3-[[[4-(二甲基氨基)苯基]亚甲基]-1H-吲哚-2-酮 (3R)-(-)-3-(1-甲基吲哚-3-基)丁酸甲酯 (3-氯-4,5-二氢-1,2-恶唑-5-基)(1,3-二氧代-1,3-二氢-2H-异吲哚-2-基)乙酸 齐多美辛 鸭脚树叶碱 鸭脚木碱,鸡骨常山碱 鲜麦得新糖 高氯酸1,1’-二(十六烷基)-3,3,3’,3’-四甲基吲哚碳菁 马鲁司特 马来酸阿洛司琼 马来酸替加色罗 顺式-ent-他达拉非 顺式-1,3,4,4a,5,9b-六氢-2H-吡啶并[4,3-b]吲哚-2-甲酸乙酯 顺式-(+-)-3,4-二氢-8-氯-4'-甲基-4-(甲基氨基)-螺(苯并(cd)吲哚-5(1H),2'(5'H)-呋喃)-5'-酮 靛红联二甲酚 靛红磺酸钠 靛红磺酸 靛红乙烯硫代缩酮 靛红-7-甲酸甲酯 靛红-5-磺酸钠 靛红-5-磺酸 靛红-5-硫酸钠盐二水 靛红-5-甲酸甲酯 靛红 靛玉红3'-单肟5-磺酸 靛玉红-3'-单肟 靛玉红 青色素3联己酸染料,钾盐 雷马曲班 雷莫司琼杂质13 雷莫司琼杂质12 雷莫司琼杂质 雷替尼卜定 雄甾-1,4-二烯-3,17-二酮 阿霉素的代谢产物盐酸盐 阿贝卡尔 阿西美辛叔丁基酯 阿西美辛 阿莫曲普坦杂质1 阿莫曲普坦 阿莫曲坦二聚体杂质 阿莫曲坦 阿洛司琼杂质